PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance

U.S. Markets close in 2 hrs 16 mins

Perrigo Company plc (PRGO)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
84.17+0.10 (+0.12%)
As of 1:44PM EST. Market open.
People also watch
MYLENDPALXNREGNTEVA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close84.07
Open84.37
Bid0.00 x
Ask0.00 x
Day's Range83.07 - 84.77
52 Week Range71.84 - 140.65
Volume681,827
Avg. Volume1,666,993
Market Cap12.07B
Beta0.67
PE Ratio (TTM)-8.35
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.64 (0.76%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    Israeli supermarket chain Shufersal Q4 profit up

    * Shufersal, Israel's largest supermarket chain, said on Wednesday net profit was up in the fourth quarter, boosted by its private label products that now account for more than a fifth of all sales. * The company posted net profit of 96 million shekels ($25.9 million), up from 77 million shekels a year earlier. Revenue slipped 1.9 percent to 2.87 billion shekels.

  • PR Newswire3 days ago

    Perrigo Company plc Announces Quarterly Dividend

    DUBLIN, Feb. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on March 21, 2017 to shareholders of record on March 3, 2017. From its beginnings in 1887 as a packager of home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from the sales of the multiple sclerosis drug Tysabri®.

  • PR Newswire7 days ago

    Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution

    DUBLIN, Feb. 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL. Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL is indicated for the symptomatic relief of cough in adults and children 6 years of age and older. Perrigo CEO John T. Hendrickson stated, "This final approval is another example of Perrigo's ongoing commitment to developing high quality value alternatives in important treatment categories.